Panbela Therapeutics, Inc. (PBLA)
OTCMKTS · Delayed Price · Currency is USD
0.0111
+0.011099 (1,109,900.00%)
At close: Sep 24, 2026
Panbela Therapeutics Earnings Call Transcripts
Fiscal Year 2024
-
Secured a $12 million strategic loan, supporting clinical progress in late-stage cancer trials and extending cash runway into Q1 2025. Key programs, including the ASPIRE and PACES trials, are advancing on schedule, with significant milestones expected in 2025.
-
ASPIRE trial enrollment is ahead of schedule, with interim analysis delayed to early 2025 due to prolonged survival, indicating potential efficacy. Q2 saw increased R&D spending and a $7.1M net loss, with liquidity supported by a $1.5M loan and milestone payments.